Major Eligibility Criteria
Key Inclusion Criteria
•
Histologically or cytologically confirmed, locally advanced and/or
metastatic, stage IIIB–IV or recurrent NSCLC
•
All NSCLC histologies
•
ECOG PS 0 or 1
•
Failure after first-line chemotherapy
Key Exclusion Criteria
•
Prior docetaxel or VEGFR inhibitors (other than bevacizumab)
•
Active brain metastases or leptomeningeal disease
•
Cavitary or necrotic tumours
Reck M, et al.
Lancet Oncol
. 2014;15:143-55.
